StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$27.55−0.49 (-1.75%)

Close on Nov 18, 2026Market cap $2.16BP/E –Yield –

Celldex Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Celldex Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$242.11M. For fiscal 2025 it was -$213.66M. The highest annual figure on record is -$30.40M in fiscal 2009.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$213.66M–
FY2024Dec 31, 2024-$159.70M–
FY2023Dec 31, 2023-$109.11M–
FY2022Dec 31, 2022-$105.56M–
FY2021Dec 31, 2021-$62.16M–
FY2020Dec 31, 2020-$41.96M–
FY2019Dec 31, 2019-$47.15M–
FY2018Dec 31, 2018-$76.05M–
FY2017Dec 31, 2017-$101.72M–
FY2016Dec 31, 2016-$115.79M–
FY2015Dec 31, 2015-$103.76M–
FY2014Dec 31, 2014-$103.47M–
FY2013Dec 31, 2013-$71.89M–
FY2012Dec 31, 2012-$50.09M–
FY2011Dec 31, 2011-$36.17M–
FY2010Dec 31, 2010-$32.47M–
FY2009Dec 31, 2009-$30.40M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$60.59M–
Q1 FY2026Mar 31, 2026-$67.23M–
Q4 FY2025Dec 31, 2025-$65.22M–
Q3 FY2025Sep 30, 2025-$49.07M–
Q2 FY2025Jun 30, 2025-$44.73M–
Q1 FY2025Mar 31, 2025-$54.64M–
Q4 FY2024Dec 31, 2024-$33.23M–
Q3 FY2024Sep 30, 2024-$55.88M–
Q2 FY2024Jun 30, 2024-$29.60M–
Q1 FY2024Mar 31, 2024-$40.98M–
Q4 FY2023Dec 31, 2023-$33.20M–
Q3 FY2023Sep 30, 2023-$19.15M–
Q2 FY2023Jun 30, 2023-$27.61M–
Q1 FY2023Mar 31, 2023-$29.15M–
Q4 FY2022Dec 31, 2022-$22.00M–
Q3 FY2022Sep 30, 2022-$35.54M–
Q2 FY2022Jun 30, 2022-$22.92M–
Q1 FY2022Mar 31, 2022-$25.11M–
Q4 FY2021Dec 31, 2021-$14.88M–
Q3 FY2021Sep 30, 2021-$16.56M–
Q2 FY2021Jun 30, 2021-$12.07M–
Q1 FY2021Mar 31, 2021-$18.65M–
Q4 FY2020Dec 31, 2020-$5.46M–
Q3 FY2020Sep 30, 2020-$12.02M–
Q2 FY2020Jun 30, 2020-$12.13M–
Q1 FY2020Mar 31, 2020-$12.35M–
Q4 FY2019Dec 31, 2019-$11.11M–
Q3 FY2019Sep 30, 2019-$11.28M–
Q2 FY2019Jun 30, 2019-$11.34M–
Q1 FY2019Mar 31, 2019-$13.42M–
Q4 FY2018Dec 31, 2018-$15.59M–
Q3 FY2018Sep 30, 2018-$14.45M–
Q2 FY2018Jun 30, 2018-$17.73M–
Q1 FY2018Mar 31, 2018-$28.28M–
Q4 FY2017Dec 31, 2017-$19.71M–
Q3 FY2017Sep 30, 2017-$24.64M–
Q2 FY2017Jun 30, 2017-$21.73M–
Q1 FY2017Mar 31, 2017-$35.64M–
Q4 FY2016Dec 31, 2016-$20.99M–
Q3 FY2016Sep 30, 2016-$24.76M–

More Celldex Therapeutics figures

See a number that looks wrong?